A Study to Compare the Efficacy and Safety of BMS-986489 (BMS-986012+ Nivolumab Fixed Dose Combination) in Combination With Carboplatin Plus Etoposide to That of Atezolizumab With Carboplatin Plus Etoposide as First-Line Therapy in Participants With Extensive-Stage Small Cell Lung Cancer (TIGOS).

Active:	Yes
Cancer Type:	Lung Cancer	NCT ID:	NCT06646276
Trial Phases:	Phase III	Protocol IDs:	CA245-0001 (primary) NCI-2025-03572
Eligibility:	18 Years and older, Male and Female	Study Type:	Treatment
Study Sponsor:	Bristol-Myers Squibb
NCI Full Details:	http://clinicaltrials.gov/show/NCT06646276

Summary

The Purpose of the Study is to Compare the Efficacy and Safety of BMS-986489
(Anti-fucosyl-GM1+ Nivolumab Fixed Dose Combination) in Combination with Carboplatin plus
Etoposide to that of Atezolizumab with Carboplatin plus Etoposide as First-Line Therapy
in Participants with Extensive-Stage Small Cell Lung Cancer.

Treatment Sites in Georgia

Northwest Georgia Oncology Centers (NGOC)
340 Kennestone Hospital Blvd.
Suite 100
Marietta, GA 3060

Study Coordinator:

Kristine Parker
470-267-1480

**Clinical trials are research studies that involve people. These studies test new ways to prevent, detect, diagnose, or treat diseases. People who take part in cancer clinical trials have an opportunity to contribute to scientists’ knowledge about cancer and to help in the development of improved cancer treatments. They also receive state-of-the-art care from cancer experts... Click here to learn more about clinical trials.